Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs

Overview of attention for article published in Frontiers in Pharmacology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,675 followers.

RT @FrontPharmacol: New Research: Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC…

30 Jun 2023

Reply Repost Favourite

RT @FrontPharmacol: New Research: Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC…

29 Jun 2023

Reply Repost Favourite

New Research: Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs #pharmacology https://t.co/kkdEjufcls

29 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.